Quantitative pharmacology approach in Alzheimer's disease: Efficacy modeling of early clinical data to predict clinical outcome of tesofensine

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 117-129

  Lehr, Thorsten ^a,b   Staab, Alexander ^b   Trommeshauser, Dirk ^b   Schaefer, Hans Guenter ^b   Kloft, Charlotte ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

ADAS COG.; Alzheimer's disease; PK PD modeling; Quantitative pharmacology; Tesofensine

Indexed keywords

DRUG METABOLITE; PLACEBO; TESOFENSINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PHARMACOLOGY; CLINICAL STUDY; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; MORNING DOSAGE; OUTCOME ASSESSMENT; PLACEBO EFFECT; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PROCESS MODEL; QUANTITATIVE ANALYSIS; RELIABILITY; RETROSPECTIVE STUDY; TREATMENT DURATION;

ALGORITHMS; ALZHEIMER DISEASE; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOGENIC MONOAMINES; CLINICAL TRIALS AS TOPIC; COGNITION; COMPUTER SIMULATION; DATABASES, FACTUAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FORECASTING; HUMANS; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; NONLINEAR DYNAMICS; POPULATION; TREATMENT OUTCOME;

EID: 77950631991     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9164-6     Document Type: Article

References (41)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-715 (Pubitemid 39173511)
2. Tufts Center for the Study of Drug Development. Impact Report: Fastest drug developers consistently best peers on key performance metrics, Tufts University, Boston, 2006.
3. US Food and Drug Administration. Innovation or Stagnation: Challenge and opportunity on the critical path to new medical products, Rockville, 2004.
4. Frantz S. Pipeline problems are increasing the urge to merge. Nat Rev. 2006;5:977-979 (Pubitemid 44841763)
5. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 2005;7:E503-12.
6. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007;82:21-32.
7. Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn. 2006;33:369-393 (Pubitemid 44020386)
8. Stanski D. Model-based drug development: a critical path opportunity. http://wwwfdagov/oc/initiatives/criticalpath/stanski/stanskihtml. Last accessed 10 Aug 2009.
9. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10:552-559
10. Association A. Alzheimer's disease facts and figures. Alzheimer's Dementia. 2009;5:234-270
11. Burns A, Iliffe S. Alzheimer's disease. Br Med J. 2009;338:467-471
12. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;373:1906-1913
13. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity. 2008;16:1363-1369 (Pubitemid 351770532)
14. Thatte U. NS-2330 NeuroSearch. Curr Opin Investig Drugs. 2001;2:1592-1594 (Pubitemid 33081079)
15. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet, 2010;49:53-66.
16. Lehr T, Staab A, Tillmann C, Trommeshauser T, Raschig A, Schaefer HG, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol. 2007;64:36-48. (Pubitemid 46934421)
17. Lehr T, Staab A, Tillmann C, Nielsen EO, Trommeshauser D, Schaefer HG, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokineticpharmacodynamic modelling approach. Br J Pharmacol. 2008; 153:164-174
18. Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet 2009;48:529-542.
19. Press release: NeuroSearch Continues the Development of Tesofensine (NS2330) and Boehringer Ingelheim Returns All Rights to NeuroSearch, 2009.
20. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277:925-926
21. Note for Guidance on Good Clinical Practice(CPMP/ICH/135/95) Step 5, Consolidated Guideline 1.5.96 including post Step 4 errata, 1996.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364
23. Beal SL, Sheiner LB, Group NP. NONMEM users guides. San Francisco: University of California; 1998.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723
25. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
26. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625-659 (Pubitemid 32385901)
27. Holford NHG, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992;89: 11471-11475
28. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495
29. Parke J, Holford NHG, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59:19-29. (Pubitemid 29125558)
30. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM-related programming. Comput Methods Programs Biomed. 2004;75:85-94. (Pubitemid 38798039)
31. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185-202.
32. Wilkinson D, Murray J. Galantamine: a randomized, doubleblind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:852-857 (Pubitemid 32926767)
33. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol. 1999;6:423-429 (Pubitemid 29371138)
34. Holford NHG, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992;89: 11466-11470
35. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.
36. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41:719-739 (Pubitemid 34948194)
37. Burns A, Rossor M, Hecker J, Gauthier S, Petit H,Mller HJ, et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244 (Pubitemid 29224502)
38. Corey-Bloom J. Galantamine: a review of its use in alzheimer's disease and vascular dementia. Int J Clin Pract. 2003;57:219-223 (Pubitemid 36511782)
39. Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer's disease a population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol. 1994;47:17-23. (Pubitemid 24281306)
40. Reisberg B, Ferris S, Doody R, St ffler A, bius HJM, Schmitt F. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341 (Pubitemid 36384100)
41. Lockwood P, Ewy W, Hermann D, Holford N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res. 2006;23:2050-2059